PGNX: Profile for Progenics Pharmaceuticals Inc. - Yahoo! Finance
See the company profile for Progenics Pharmaceuticals Inc. (PGNX) including business summary, industry/sector information, number of employees, ...
http://biz.yahoo.com/p/p/pgnx.html...
|
Wyeth and Progenics Announce Preliminary Clinical Trial Results ...
22 May 2008 ... The Progenics-conducted phase 3 study of an intravenous formulation of RELISTOR for patients with post-operative ileus (POI) did not meet ...
http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home...
|
BioSpace - Progenics Pharmaceuticals, Inc. News, Search Jobs, Events
Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic ...
http://www.biospace.com/company_profile.aspx?CompanyId=2587...
|
Wyeth and Progenics Receive Approval From European Commission For ...
3 Jul 2008 ... In December 2005, Wyeth and Progenics Pharmaceuticals entered into an exclusive, worldwide agreement for the joint development and ...
http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home...
|
Progenics Announces Wyeth Has Received RELISTOR Approval in ...
Progenics Announces Wyeth Has Received RELISTOR Approval in Australia. - TARRYTOWN, NY--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX
...
http://biz.yahoo.com/bw/081117/20081117005809.html?.v=1...
|
Progenics and Wyeth Announce NDA Review Period for Subcutaneous ...
10 Jan 2008 ... In March 2007, Progenics submitted a new drug application (NDA) to the FDA for subcutaneous methylnaltrexone, followed in May 2007 by ...
http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home...
|
News: Ono Obtains Japanese License for Progenics' Constipation ...
17 Oct 2008 ... Ono Obtains Japanese License for Progenics' Constipation Therapy for $15M. Genetic Engineering & Biotechnology News - Biotechnology from ...
http://www.genengnews.com/news/bnitem.aspx?name=43697232...
|
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of ...
12 Mar 2008 ... The second phase 3 trial of intravenous methylnaltrexone for management of POI is being led by Progenics and is similar in design to the ...
http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home...
|
Progenics Reports Third Quarter 2008 Financial Results and ...
Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates. - TARRYTOWN, NY--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: ...
http://biz.yahoo.com/bw/081110/20081110005503.html?.v=1...
|
Wyeth And Progenics Receive Positive Opinion From European ...
24 Apr 2008 ... In March 2007, Progenics submitted a New Drug Application for subcutaneous RELISTOR for the treatment of opioid-induced constipation (OIC) ...
http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home...
|
